{"id":387799,"date":"2020-11-24T10:03:26","date_gmt":"2020-11-24T15:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387799"},"modified":"2020-11-24T10:03:26","modified_gmt":"2020-11-24T15:03:26","slug":"bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/","title":{"rendered":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020"},"content":{"rendered":"
\n

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between\u00a0February 28, 2020 and August 18, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm\u2019s site: www.bgandg.com\/bmrn<\/a>.\u00a0 \u00a0 \u00a0 \u00a0<\/p>\n

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.<\/p>\n

The Complaint alleges that \u00a0throughout the Class Period, Defendants made materially false and misleading statements\u00a0that: (1) differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1\/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would not approve the Biologics License Application (“BLA”) for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.\u00a0<\/p>\n

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm\u2019s site: www.bgandg.com\/bmrn<\/a> or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in BioMarin you have until November 24, 2020 to request that the Court appoint you as lead plaintiff.\u00a0 Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.\u00a0 Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.\u00a0 In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm\u2019s expertise includes general corporate and commercial litigation, as well as securities arbitration.\u00a0 \u00a0Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between\u00a0February 28, 2020 and August 18, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm\u2019s site: www.bgandg.com\/bmrn.\u00a0 \u00a0 \u00a0 \u00a0 This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that \u00a0throughout the Class Period, Defendants made materially false and misleading … <\/p>\n

Continue reading “BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between\u00a0February 28, 2020 and August 18, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm\u2019s site: www.bgandg.com\/bmrn.\u00a0 \u00a0 \u00a0 \u00a0 This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that \u00a0throughout the Class Period, Defendants made materially false and misleading … Continue reading "BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T15:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020\",\"datePublished\":\"2020-11-24T15:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/\"},\"wordCount\":379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/\",\"name\":\"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=\",\"datePublished\":\"2020-11-24T15:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/","og_locale":"en_US","og_type":"article","og_title":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk","og_description":"NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin securities between\u00a0February 28, 2020 and August 18, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm\u2019s site: www.bgandg.com\/bmrn.\u00a0 \u00a0 \u00a0 \u00a0 This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that \u00a0throughout the Class Period, Defendants made materially false and misleading … Continue reading \"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T15:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020","datePublished":"2020-11-24T15:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/"},"wordCount":379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/","name":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=","datePublished":"2020-11-24T15:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDQ0OCMzODI3Nzc2IzIwMTc2OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-final-deadline-bronstein-gewirtz-grossman-llc-reminds-biomarin-pharmaceutical-inc-investors-with-losses-exceeding-100k-of-class-action-and-lead-plaintiff-deadline-november-24-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}